Ustekinumab, Ozanimod Have Comparable Profiles for Ulcerative Colitis
Marla Dubinsky, MD, discusses a study at the Digestive Disease Week conference in San Diego finding a lot of similarities in efficacy and safety for ozanimod and ustekinumab in treating patients with ulcerative colitis. "Mirikizumab is the first IL-23 p19-targeted biologic demonstrating efficacy in a phase III trial of patients with moderately to severely active UC [ulcerative colitis] regardless of biologic or tofacitinib failed status," she said.
Tags:
Marla C Dubinsky, MD
